Cafepharma Today

June 6 2025 - Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
Novartis presses court for hasty decision in long-running Entresto patent feud with MSN
'Not a horse and pony show': At FDA cell and gene roundtable, officials look for ways to cut red tape
With ADCs on the rise, drugmakers embrace a new oncology pillar
Bayer trial combines two top drugs for kidney disease
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

IDEAYA’s rare cancer drug shows promise as company lays out Phase III plans
Clinical Trials Arena
Tuesday, September 24, 2024 - 11:54am
tags:
IDEAYA Biosciences, clinical trials, darovasertib, neoadjuvant uveal melanoma
Inside the GLP-1 'price war'
Beckers Hospital Review
Tuesday, September 24, 2024 - 11:52am
tags:
GLP-1 agonists, obesity, weight loss, Eli Lilly, Novo Nordisk, Ozempic, Wegovy, Zepbound, Mounjaro, drug pricing
Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
Clinical Trials Arena
Tuesday, September 24, 2024 - 11:51am
tags:
Arrowhead Pharmaceuticals, clinical trials, ARO-INHBE, RNAi, obesity, New Zealand
Inside JNJ’s Gross-to-Net Bubble
Drug Channels
Tuesday, September 24, 2024 - 11:49am
tags:
JNJ Innovation
Wave surfs DMD success to regulators' doors, sending stock up
Fierce Biotech
Tuesday, September 24, 2024 - 11:45am
tags:
Wave Life Sciences, DMD, Duchenne Muscular Dystrophy, clinical trials
Aptadir going after cancer, genetic diseases with new class of RNA inhibitors
First Word Pharma
Tuesday, September 24, 2024 - 11:42am
tags:
Aptadir Thrapeutics, RNA therapeutics, funding
Novartis inks $1B-plus biobucks deal with Flagship's Generate
Fierce Biotech
Tuesday, September 24, 2024 - 11:41am
tags:
Novartis, Generate Biomedicines, protein therapeutics
U.S. Senator Sanders says pharmacy middlemen commit to expanding weight-loss drug coverage if prices cut
Reuters
Tuesday, September 24, 2024 - 11:40am
tags:
Bernie Sanders, PBMs, Novo Nordisk, Ozempic, Wegovy, drug pricing
Eli Lilly's Alzheimer's drug approved in Japan
Reuters
Tuesday, September 24, 2024 - 11:39am
tags:
Eli Lilly, Japan, donanemab, Alzheimer's disease
UCB, Biogen lupus drug scores in phase 3 trial
Pharmaphorum
Tuesday, September 24, 2024 - 11:37am
tags:
UCB Pharma, Biogen, systemic lupus erythematosus, clinical trials, dapirolizumab pegol
Bluebird bio lays off 25% of workforce as gene therapy pioneer struggles to stay afloat
Fierce Pharma
Tuesday, September 24, 2024 - 11:35am
tags:
Bluebird Bio, layoffs, gene therapy
Sanofi CEO believes company poised for growth from new drugs
Reuters
Monday, September 23, 2024 - 10:32pm
tags:
Sanofi, Pharma CEOs, Paul Hudson
Novo says Ozempic to be eligible for US price negotiations in less than a year
Reuters
Monday, September 23, 2024 - 10:27pm
tags:
Novo Nordisk, Ozempic, drug pricing
Johnson & Johnson Files for Bankruptcy Over Talc Lawsuits for the Third Time
Yahoo/Zacks.com
Monday, September 23, 2024 - 10:25pm
tags:
JNJ, legal, bankruptcy
Startup Vicebio banks $100M in bid to make ‘cost-effective’ vaccines
BioPharma Dive
Monday, September 23, 2024 - 10:24pm
tags:
Vicebio, vaccines, funding
UCB rapidly bolsters blockbuster potential for Bimzelx with 3 new FDA approvals
Fierce Pharma
Monday, September 23, 2024 - 10:19pm
tags:
UCB Pharma, Bimzelx, FDA, psoriatic arthritis, radiographic axial spondyloarthritis, ankylosing spondylitis
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson’s candidate for $27M
Fierce Biotech
Monday, September 23, 2024 - 11:33am
tags:
Sanofi, Ventyx Biosciences, obesity, Parkinson's Disease
Appeals Court Breathes New Life Into PhRMA’s Legal Challenge to IRA
BioSpace
Monday, September 23, 2024 - 11:31am
tags:
PhRMA, legal, Inflation Reduction Act, drug pricing
AstraZeneca's experimental drug disappoints in breast cancer survival trial
Reuters
Monday, September 23, 2024 - 11:29am
tags:
AstraZeneca, Daiichi Sankyo, clinical trials, breast cancer, Dato-DXd
Teva touts safety profile of once-monthly schizophrenia therapy
Clinical Trials Arena
Monday, September 23, 2024 - 11:17am
tags:
Teva Parmceuticals, TEV-749, Olanzapine, schizophrenia

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Taurine and Aging: Is There Anything to It?
In the Pipeline
Cleaning Up the Medical Literature
In the Pipeline
Not One of Your Easy Crystals
In the Pipeline
The Continuing Crisis, Part XV: The Horrendous Trump Budget
In the Pipeline
Taurine Revisited
In the Pipeline
A New Route to Asthma Treatment - Through the Liver, of All Places
In the Pipeline
One Drug's Supply Chain, In Detail
In the Pipeline
A Reaction to Alzheimer's Fraud
In the Pipeline
Whoa Now: Cautionary Tales from Materials Science
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.